ACRO BIOMEDICAL LTD
AI Executive Summary
AI-powered analysis of 10-K filing content
ACRO BIOMEDICAL LTD reports zero revenue since December 31, 2022, highlighting significant financial distress and operational challenges.
The most significant changes observed in ACRO Biomedical Ltd's current filing include a complete absence of revenue generation since December 31, 2022, and significant operating losses increasing from $42,000 in 2024 to approximately $101,000 in 2025. The company has also recognized a provision for doubtful accounts of $480,000 for uncollectible receivables. Overall, financial stability seems to have deteriorated as cash reserves and total assets sharply declined.
Key figures from the filing
- ▸The company experienced losses of approximately $101,000 and $42,000 in the years 2025 and 2024, respectively, indicating deteriorating financial performance.
- ▸Revenue generation has ceased with no sales reported in the second and third quarters of 2022, leading to significant operational concerns.
- ▸For the year ended December 31, 2022, all revenue came from only two customers, underscoring customer concentration risk in the business model.
Red Flags Detected (2)
Deteriorating total asset quality and cash flow, with cash reduced by over 90% compared to previous years.
Absence of revenue generation over multiple quarters indicates severe underlying business issues.
Key Takeaways
Investors should pay close attention to the sustainability of operations given the current lack of sales.
The investment thesis has changed, shifting towards caution due to increased financial risks and potential insolvency.
2 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Annual Report: Comprehensive filing covering the full fiscal year with audited financial statements.